Pediatric dyslipidemias: Prescription medication efficacy and safety

Browne, Barry; Vasquez, Susie

doi:10.1016/j.jacl.2008.04.008

Cited by 6 publications

(4 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14 There is some reluctance to use dyslipidemic therapies in pediatric populations when lifestyle modifications do not attenuate elevated TG levels; this philosophy, however, is changing, and randomized clinical studies in pediatric populations are currently under way to evaluate the safety and effectiveness of specific lipid-lowering drugs used in adult populations. 13,15 In our study, statins were the most commonly prescribed dyslipidemic agent.…”

Section: Discussionmentioning

confidence: 64%

Prevalence, Characteristics, and Risk Factors of Elevated Triglyceride Levels in US Children

Christian

Juneja

Meadowcroft

et al. 2011

Clin Pediatr (Phila)

View full text Add to dashboard Cite

Limited information is available on the epidemiology of hypertriglyceridemia (HTG; 150-499 mg/dL) and severe HTG (SHTG; >500 mg/dL) in children. This study estimates the prevalence of HTG and SHTG, evaluates factors that may be associated with these conditions, and describes the use of dyslipidemic agents in children. The sample included children 12 to 19 years old who participated in National Health and Nutrition Examination Survey (NHANES) 2001-2008 (n = 3248) and children 5 to 19 years of age who were part of a large managed-care claims database in the United States (n = 65 258). Results from NHANES confirm the rarity of SHTG in the US pediatric population (ie, 0.2%). Factors statistically significantly associated with having HTG or SHTG in the claims database were being male, 12 to 19 years old, having high low-density lipoprotein (LDL), having low high-density lipoprotein (HDL), diabetes, and psychological disorders. Fibrates were the most commonly prescribed triglyceride-lowering agent among children with SHTG, followed by statins and Lovaza.

show abstract

Section: Discussionmentioning

confidence: 64%

Prevalence, Characteristics, and Risk Factors of Elevated Triglyceride Levels in US Children

Christian

Juneja

Meadowcroft

et al. 2011

Clin Pediatr (Phila)

View full text Add to dashboard Cite

show abstract

“…la hF homocigota se asocia a ae rápidamente progresiva, eventos cardiovasculares, alta mortalidad en la segunda década y casos extremos en la niñez. Sin embargo, las hipercolesterolemias aisladas más frecuentes son las poligénicas, su magnitud es menor y la respuesta a la dieta es aceptable [27][28][29] . el objetivo del tratamiento es disminuir el c-ldl entre 30-50% y en lo posible alcanzar concentraciones < 130 mg/dL 17 .…”

Section: Tratamiento De Las Dislipidemiasunclassified

“…como rama de nutrición consideramos prudente iniciar fibratos en niños > 10 años que persistan con TG > 900 mg/dL después de al menos 6 meses de adecuado manejo no farmacológico. La dosis de fenofibrato es de 5 mg/kg/día, aunque no está aprobado por la Fda en niños 28 .…”

Section: Tratamiento Farmacológicounclassified

Diagnóstico y tratamiento de las dislipidemias en niños y adolescentes: Recomendaciones de la Rama de Nutrición de la Sociedad Chilena de Pediatría

et al. 2014

Rev. chil. pediatr.

View full text Add to dashboard Cite

“…Different concerns existed such as possible negative effects on muscles, growth and/or maturation, and potential teratogenicity in a population that includes adolescent females (Sibley & Stone, 2006;Belay et al, 2007). Despite the fact that these are all theoretical concerns with scares clinical evidences, long-term administration remained definitely an important risk (Browne & Vasquez, 2008).…”

Section: Introductionmentioning

confidence: 99%

Assessment of simvastatin niosomes for pediatric transdermal drug delivery

et al. 2014

View full text Add to dashboard Cite

The prevalence of childhood dyslipidemia increases and is considered as an important risk factor for the incidence of cardiovascular disease in the adulthood. To improve dosing accuracy and facilitate the determination of dosing regimens in function of the body weight, the proposed study aims at preparing transdermal niosomal gels of simvastatin as possible transdermal drug delivery system for pediatric applications. Twelve formulations were prepared to screen the influence of formulation and processing variables on critical niosomal characteristics. Nano-sized niosomes with 0.31 mm number-weighted size displayed highest simvastatin release rate with 8.5% entrapment capacity. The niosomal surface coverage by negative charges was calculated according to Langmuir isotherm with n ¼ 0.42 to suggest that the surface association was site-independent, probably producing surface rearrangements. Hypolipidemic activities after transdermal administration of niosomal gels to rats showed significant reduction in cholesterol and triglyceride levels while increasing plasma high-density lipoproteins concentration. Bioavailability estimation in rats revealed an augmentation in simvastatin bioavailability by 3.35 and 2.9 folds from formulation F3 and F10, respectively, compared with oral drug suspension. Hence, this transdermal simvastatin niosomes not only exhibited remarkable potential to enhance its bioavailability and hypolipidemic activity but also considered a promising pediatric antihyperlipidemic formulation.

show abstract

Pediatric dyslipidemias: Prescription medication efficacy and safety

Cited by 6 publications

References 60 publications

Prevalence, Characteristics, and Risk Factors of Elevated Triglyceride Levels in US Children

Prevalence, Characteristics, and Risk Factors of Elevated Triglyceride Levels in US Children

Diagnóstico y tratamiento de las dislipidemias en niños y adolescentes: Recomendaciones de la Rama de Nutrición de la Sociedad Chilena de Pediatría

Assessment of simvastatin niosomes for pediatric transdermal drug delivery

Contact Info

Product

Resources

About